Francesco Lechi, Amina Khalil, Pablo Novales Bautista, Jakob Öberg, Lorenzo Jacopo Ilic Balestri, Olof Eriksson, Jonas Eriksson, Luke R. Odell
{"title":"Radiosynthesis and preclinical evaluation of [11C]Methyl-V-0219, a small molecule glucagon-like peptide-1 allosteric modulator for PET brain imaging","authors":"Francesco Lechi, Amina Khalil, Pablo Novales Bautista, Jakob Öberg, Lorenzo Jacopo Ilic Balestri, Olof Eriksson, Jonas Eriksson, Luke R. Odell","doi":"10.1186/s41181-026-00486-4","DOIUrl":"10.1186/s41181-026-00486-4","url":null,"abstract":"<div><h3>Background</h3><p>Glucagon-like peptide-1 receptor (GLP-1R) is a clinically validated therapeutic target for the treatment of obesity and type 2 diabetes. GLP-1Rs expressed in the central nervous system (CNS) regulate appetite and are therefore particularly important in the context of weight loss. There is thus an emerging need for efficient and brain-penetrating Positron Emission Tomography (PET) technologies to study the distribution of GLP-1R in the CNS and facilitate the development of novel GLP-1R-targeted therapeutics. However, currently established GLP-1R PET tracers are peptide-based and exhibit limited blood–brain barrier (BBB) penetration, restricting their use for imaging central GLP-1R expression. V-0219, a small molecule GLP-1R positive allosteric modulator, represents a potential scaffold for the development of BBB-penetrating PET tracers targeting incretin receptor systems in the brain.</p><h3>Results</h3><p>Here, we report the radiosynthesis and preclinical evaluation of [<sup>11</sup>C]Methyl-V-0219, a carbon-11 labelled analogue of V-0219. [<sup>11</sup>C]Methyl-V-0219 was synthesized using a Pd(0)-mediated Suzuki–Miyaura coupling reaction and obtained with a radiochemical yield of 36 ± 18% (n = 16) and radiochemical purity of 98.6 ± 1.6% (n = 16). In vitro autoradiography demonstrated retained binding to GLP-1R–positive tissues, although binding to glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors was also observed.</p><p>In vivo PET imaging was performed in rats and pigs and compared with the well-established GLP-1R tracer [<sup>68</sup>Ga]Ga-DO3A-Exendin-4. Dynamic PET imaging demonstrated rapid brain uptake of [<sup>11</sup>C]Methyl-V-0219 followed by progressive washout, indicating BBB penetration but limited retention in the brain. In contrast to [<sup>68</sup>Ga]Ga-DO3A-Exendin-4, [<sup>11</sup>C]Methyl-V-0219 did not demonstrate detectable retention in GLP-1R–rich tissues, including the pituitary gland and pancreas. Instead, prominent uptake was observed in the liver, intestines, and glandular tissues, consistent with hepatobiliary clearance and nonspecific accumulation of a lipophilic compound. Furthermore, blocking and competition studies did not alter tracer brain kinetics, suggesting no detectable displaceable binding in vivo.</p><h3>Conclusion</h3><p>Taken together, these findings demonstrate the feasibility of developing small–molecule–based PET tracers targeting incretin receptor systems, while highlighting the challenges associated with achieving sufficient in vivo specificity for brain GLP-1R imaging.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00486-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148782001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stable core-encapsulation of indium-111 in crosslinked polyionic complex micelles and assessment of its biodistribution","authors":"Hayato Laurence Mizuno, Sotaro Miyao, Hiroyuki Takahashi, Nobuyoshi Akimitsu, Yasutaka Anraku","doi":"10.1186/s41181-026-00478-4","DOIUrl":"10.1186/s41181-026-00478-4","url":null,"abstract":"<div><h3>Background</h3><p>Radioactive isotopes, such as Indium-111 (<sup>111</sup>In), are pivotal for highly sensitive noninvasive imaging and targeted radiotherapy. However, achieving stable in vivo retention remains a critical barrier. Conventional nanocarriers typically rely on surface-bound chelators, exposing the isotopes to biological transchelation and detachment, while potentially altering the carrier’s surface properties and pharmacokinetics. To address these limitations, this study evaluates a polyionic complex micelle (PICm) platform designed to encapsulate <sup>111</sup>In within a crosslinked core using DOTA chelation. This approach aims to enhance radiochemical stability while preserving the micelle’s native, engineered surface characteristics.</p><h3>Results</h3><p>DOTA-functionalized PICm were fabricated through electrostatic self-assembly of PEG-based polymers and subsequent core crosslinking. The resulting micelles exhibited a highly uniform size (32.6 ± 6.3 nm) and a modestly negative surface charge (− 4.9 ± 1.0 mV). Stability assays demonstrated that under the acidic conditions required for <sup>111</sup>In chelation (pH 5.5), the micelles undergo reversible size swelling driven by polymer protonation without aggregating or collapsing, confirming that core crosslinking successfully maintains micellar integrity. In vivo biodistribution in CT26 tumor-bearing mice revealed that <sup>111</sup>In-loaded PICm displayed prolonged systemic presence, with tumor accumulation peaking at 2.3 ± 0.4%ID/g at 24 h post-injection via the enhanced permeability and retention effect. Hepatic and splenic uptakes aligned with typical nanoparticle clearance pathways.</p><h3>Conclusions</h3><p>The core-loading of PICm may offer advantages over surface-chelated nanocarriers. By maintaining structural integrity during radiolabeling and extending systemic circulation in vivo, these results validate the platform’s robustness and passive tumor accumulation, highlighting its potential as a versatile vehicle for the delivery of diagnostic radionuclides.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmad Kurniawan, Zihe Ming, Melody E Boëtius, Nerea Delgado Mayenco, Simon N Blok, Wiktor Szymanski, Philip H Elsinga, Inês Farinha Antunes, Erik F J de Vries, Bart Cornelissen
{"title":"Radiometal-labelled derivatives of olaparib do not permeate cell membranes.","authors":"Ahmad Kurniawan, Zihe Ming, Melody E Boëtius, Nerea Delgado Mayenco, Simon N Blok, Wiktor Szymanski, Philip H Elsinga, Inês Farinha Antunes, Erik F J de Vries, Bart Cornelissen","doi":"10.1186/s41181-026-00475-7","DOIUrl":"https://doi.org/10.1186/s41181-026-00475-7","url":null,"abstract":"<p><strong>Background: </strong>Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP), a nuclear protein that plays a role in DNA damage repair, are promising candidates for targeted radionuclide therapy to treat PARP-expressing cancers. Here, we evaluated the potential of a PARP inhibitor with an olaparib-like structure, labelled with the radiometals <sup>161</sup>Tb or <sup>68</sup>Ga through a DOTA chelator, for targeted radionuclide therapy and PET imaging using in vitro models of cancer.</p><p><strong>Methods: </strong>[<sup>161</sup>Tb]TbCl<sub>3</sub> and [<sup>68</sup>Ga]GaCl<sub>3</sub> were used for radiolabelling a DOTA-conjugated derivative of the PARP inhibitor olaparib, yielding [<sup>161</sup>Tb]Tb-DOTA-olaparib and [<sup>68</sup>Ga]Ga-DOTA-olaparib, respectively. Both compounds were evaluated in vitro for cell uptake, internalisation, selectivity, and effect on clonogenic survival across a panel of PARP-expressing human and murine cancer cell lines.</p><p><strong>Results: </strong>[<sup>161</sup>Tb]Tb-DOTA-olaparib and [<sup>68</sup>Ga]Ga-DOTA-olaparib were successfully produced with > 95% labelling efficiency and apparent molar activities of up to 40 and 20 MBq/nmol, respectively. Both radiolabelled compounds exhibited minimal uptake across all cancer cell lines tested. The compounds remained mainly associated with the cell membrane, with no significant internalisation detected. Neither cell association nor internalisation could be blocked using an excess of olaparib as a PARP-specific competitor ligand. The highly hydrophilic nature of both compounds, as indicated by a log D<sub>7.4</sub> value of - 3.1 ± 0.07 for [<sup>161</sup>Tb]Tb-DOTA-olaparib and - 2.8 ± 0.02 for [<sup>68</sup>Ga]Ga-DOTA-olaparib, likely contributes to their limited ability to traverse cell membranes, thereby restricting intracellular access, necessary for targeting intranuclear PARP. Clonogenic survival of cells exposed to [<sup>161</sup>Tb]Tb-DOTA-olaparib was similar to that observed for cells exposed to [<sup>161</sup>Tb]Tb-DOTA.</p><p><strong>Conclusion: </strong>[<sup>161</sup>Tb]Tb-DOTA-olaparib and [<sup>68</sup>Ga]Ga-DOTA-olaparib exhibit negligible cellular uptake and consequently show insufficient specific binding to intranuclear PARP in cancer cells. Their limited ability to penetrate the cell membrane and interact with intracellular targets makes them unsuitable for effective PARP-targeted therapy or imaging applications.</p>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shakera Khatoon, Amna Javed, Qaiser Khan, Kaleem Abbas
{"title":"High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands","authors":"Shakera Khatoon, Amna Javed, Qaiser Khan, Kaleem Abbas","doi":"10.1186/s41181-026-00474-8","DOIUrl":"10.1186/s41181-026-00474-8","url":null,"abstract":"<div><h3>Background</h3><p>Terbium-161 (<sup>161</sup> Tb) is an emerging therapeutic radionuclide combining β⁻ emission with a high yield of Auger electrons and conversion electrons, enabling enhanced localized dose deposition. However, its widespread clinical adoption is limited by inefficient target utilization and multistep post-irradiation processing. This study aimed to develop a simplified high-yield production and direct chloride-based purification workflow for clinical-grade terbium-161 using thin-layer enriched gadolinium-160 targets under limited-resource reactor conditions. Terbium-161 was produced by neutron irradiation of enriched Gadolinium-160 targets fabricated as conventional oxide powder and novel thin-layer chloride films at a thermal neutron flux of 1.5 × 10<sup>14</sup> n cm⁻<sup>2</sup> s⁻<sup>1</sup> for 24 h in Pakistan Atomic Research Reactor-1 (PARR-I). Post-irradiation separation of terbium was carried out using LN resin employing HCl and HNO₃ media, and compared with α-hydroxyisobutyric acid (α-HIBA) cation-exchange chromatography. Radionuclidic purity was assessed by HPGe γ spectrometry, while radiochemical purity and labeling efficiency with DOTA conjugated Peptides were evaluated using ITLC and HPLC.</p><h3>Results</h3><p>Thin-layer targets significantly enhanced neutron utilization, compared to oxide targets due to reduced self-shielding of target. The specific activities achieved across three production batches (34.25–79.01 MBq/mg) demonstrated an approximately 2.3-fold higher specific activity with <sup>160</sup>GdCl<sub>3</sub> layered targets than bulk Gd₂O₃ targets. LN–HCl separation provided superior recovery (91.4%) and enabled direct formulation of [<sup>161</sup> Tb]TbCl₃, eliminating post-processing steps required in nitrate systems and cation exchange with α -HIBA. Radionuclidic purity exceeded 99.99%, with minimal Terbium-160 impurity and Radiolabeling yields with DOTA-conjugated peptides exceeded 95.0%.</p><h3>Conclusion</h3><p>Target geometry plays a critical role in reactor-based radionuclide production. The integrated thin-layer target and chloride-based separation workflow provides a simplified, high-yield approach for production of terbium-161, enables efficient radiolabeling with DOTA-based ligands. These findings provide a foundation for further analytical qualification required for preclinical and clinical translations.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edla Kerminen, Thomas Keller, Simo Salo, Johan Rajander, Olof Solin, Anna Krzyczmonik, Anna K. Kirjavainen
{"title":"High molar activity [11C]phosgene from [11C]CO2","authors":"Edla Kerminen, Thomas Keller, Simo Salo, Johan Rajander, Olof Solin, Anna Krzyczmonik, Anna K. Kirjavainen","doi":"10.1186/s41181-026-00472-w","DOIUrl":"10.1186/s41181-026-00472-w","url":null,"abstract":"<div><h3>Background</h3><p>[<sup>11</sup>C]Phosgene is a known but underutilised labelling synthon in PET-tracer development. The production of [<sup>11</sup>C]phosgene faces many problems such as difficulties in achieving high molar activity, regular key component replacement and complexity of the synthesis, thereby hindering its wider use. In this paper, a robust and semi-automated synthesis route for production of [<sup>11</sup>C]phosgene from [<sup>11</sup>C]CO<sub>2</sub> was developed to solve issues restricting the use of [<sup>11</sup>C]phosgene. The high molar activity [<sup>11</sup>C]phosgene was then used for the labelling of biologically important molecules as a proof of concept.</p><h3>Results</h3><p>[<sup>11</sup>C]Phosgene was synthesized from [<sup>11</sup>C]CO by UV-mediated photochemical chlorination with chlorine gas. [<sup>11</sup>C]CO was produced by the fluoride-activated disilane reduction of cyclotron-produced [<sup>11</sup>C]CO<sub>2</sub>. [<sup>11</sup>C]Phosgene was produced with satisfactory radiochemical yield (13 ± 1 GBq at EOS, 30 ± 4% dc. to SOS) based on [<sup>11</sup>C]CO<sub>2</sub> and molar activity of 249 ± 40 GBq/µmol at EOS (n = 3). The radiosynthesis time was approximately 20 min.</p><h3>Conclusion</h3><p>A robust synthesis route for production of high molar activity [<sup>11</sup>C]phosgene from [<sup>11</sup>C]CO<sub>2</sub> was developed. The simplicity and mild reaction conditions of the [<sup>11</sup>C]CO production method used eliminate the previous issues with Zn-based reduction of [<sup>11</sup>C]CO<sub>2</sub>. Intermediate purification of [<sup>11</sup>C]CO guaranteed efficient [<sup>11</sup>C]phosgene production, and removal of unreacted Cl<sub>2</sub> minimised unwanted side reactions. This method utilises a fixed-line device with simple set up and mild conditions. With this method, it is possible to perform syntheses reliably with good radiochemical yields and high molar activities in a short synthesis time.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Le Li, Hanyue Ma, Amber Piet, Corrina de Ridder, Debra Stuurman, Priciana Paraïso, Yann Seimbille
{"title":"eFAP-51, a novel FAPI dimer with enhanced tumor uptake and retention for theranostic applications","authors":"Le Li, Hanyue Ma, Amber Piet, Corrina de Ridder, Debra Stuurman, Priciana Paraïso, Yann Seimbille","doi":"10.1186/s41181-026-00481-9","DOIUrl":"10.1186/s41181-026-00481-9","url":null,"abstract":"<div><h3>Background</h3><p>Overexpression of fibroblast activation protein (FAP) in cancer-associated fibroblasts enables a highly selective targeting strategy using FAP inhibitors. However, radiolabeled small-molecule FAP inhibitors (FAPIs) show limited tumor retention, restricting therapeutic applications. Multimerization represents a promising strategy to enhance tumor uptake and retention through polyvalent binding. Here, we report the rational design and evaluation of dimeric FAP-targeted radiopharmaceuticals for theranostic applications.</p><h3>Results</h3><p>Based on the (4-quinolinoyl)-glycyl-2-cyanopyrrolidine (QCP) scaffold, a series of monomeric FAPIs were assembled into dimeric radioligands using three distinct tripod-based platforms and equipped with a DOTA-GA chelator for efficient radiolabeling with indium-111 and lutetium-177; systematic in vitro and in vivo evaluation of binding affinity, stability, cellular uptake, and tumor targeting identified eFAP-51 and eFAP-52 as lead candidates, both showing high radiochemical yield and purity, favorable stability, and sub-nanomolar affinity for FAP with strong selectivity over DPP4. Further studies demonstrated superior tumor targeting and pharmacokinetics for eFAP-51 compared with the clinical reference FAPI-46, with [<sup>111</sup>In]In-eFAP-51 exhibiting more than 4-fold higher tumor uptake at 48 h post-injection (3.2 ± 0.5 vs. 0.71 ± 0.1%ID/g) and prolonged retention. eFAP-51 was subsequently radiolabeled with lutetium-177 to yield a stable therapeutic candidate, and dose-dependent studies revealed that intermediate molar doses (0.3–0.6 nmol) provided an optimal balance between tumor uptake and tumor-to-background contrast.</p><h3>Conclusions</h3><p>The FAPI dimer eFAP-51 showed favorable tumor targeting and pharmacokinetics, supporting its potential for clinical translation in theranostic oncology.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Radiosynthesis and quality control testing of two 18F-labeled radiopharmaceuticals for α-synuclein imaging in clinical investigations","authors":"Hiroki Hashimoto, Takayuki Ohkubo, Kazunori Kawamura, Tomoya Fujishiro, Daisuke Arashi, Tatsuto Sato, Takeru Seki, Masatoshi Muto, Kaito Tsukagoe, Masanao Ogawa, Yusuke Kurihara, Nobuki Nengaki, Wakana Mori, Masayuki Fujinaga, Makoto Higuchi, Ming-Rong Zhang","doi":"10.1186/s41181-026-00480-w","DOIUrl":"10.1186/s41181-026-00480-w","url":null,"abstract":"<div><h3>Background</h3><p><sup>18</sup>F-Labeled (<i>E</i>)-1-fluoro-3-((2-(4-(5-(methylamino)pyrazin-2-yl)but-1-en-3-yn-1-yl)benzo[<i>d</i>]thiazol-6-yl)oxy)propan-2-ol ([<sup>18</sup>F]SPAL-T-06) and (<i>E</i>)-1-fluoro-3-((2-(4-(6-(methylamino)pyridine-3-yl)but-1-en-3-yn-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol ([<sup>18</sup>F]C05-05) are positron emission tomography (PET) imaging agents for α-synuclein pathologies. Recently, we demonstrated the utility of PET imaging with [<sup>18</sup>F]SPAL-T-06 for α-synuclein pathologies in patients with multiple system atrophy and with [<sup>18</sup>F]C05-05 for α-synuclein pathologies in Parkinson’s disease and related disorders. In this study, to establish [<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05 as PET radiopharmaceuticals for clinical investigations, we developed routine radiosynthetic procedures using an <sup>18</sup>F-labeling synthesizer and performed quality control (QC) testing of these two PET radiopharmaceuticals.</p><h3>Results</h3><p>[<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05 were synthesized by direct <sup>18</sup>F-fluorination of their respective tetrahydropyranyl-protected tosylated precursors, followed by deprotection, using an <sup>18</sup>F-labeling synthesizer. The non-decay-corrected radiochemical yields of [<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05 from <sup>18</sup>F<sup>−</sup> at the end of synthesis (EOS) were 11 ± 4.6% (<i>n</i> = 19) and 20 ± 6.8% (<i>n</i> = 37), respectively. The radiochemical purities of both PET radiopharmaceuticals exceeded 99%. The molar activities of each PET radiopharmaceutical at EOS exceeded 68 GBq/µmol, and the total synthesis times were within 100 min after irradiation. In addition, [<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05 were efficiently separated from byproducts using a semi-preparative high-performance liquid chromatography system. All QC results for the two PET radiopharmaceuticals complied with in-house QC and quality assurance specifications. The stabilities of the two PET radiopharmaceuticals were evaluated under standard fluorescent light in a general laboratory environment and under UV-cutoff light in a natural light-shielded environment. After 10 min of exposure to the standard fluorescent light, the radiochemical purity of each tracer decreased to approximately 86%. In contrast, the radiochemical purity of each tracer exceeded 99% after 60 min under UV-cutoff light in a natural light-shielded environment.</p><h3>Conclusions</h3><p>We successfully prepared two PET radiopharmaceuticals, [<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05, for clinical investigation. The radiosynthesis and QC findings provide a practical basis for establishing standardized production procedures and facilitating technology transfer to other PET centers. In particularly, all post-deprotection radiosynthesis steps and QC testing for [<sup>18</sup>F]SPAL-T-06 and [<sup>18</sup>F]C05-05 should be performed under ","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gina Kaup, Jason Anthony Witek, Shelbie Jaylene Cingoranelli, Jenelle Stauff, David Raffel, Allen Frederick Brooks, Peter James Henry Scott, Jay Samuel Wright
{"title":"Automated radiosynthesis and biodistribution of [18F]fluoroflutamide","authors":"Gina Kaup, Jason Anthony Witek, Shelbie Jaylene Cingoranelli, Jenelle Stauff, David Raffel, Allen Frederick Brooks, Peter James Henry Scott, Jay Samuel Wright","doi":"10.1186/s41181-026-00453-z","DOIUrl":"10.1186/s41181-026-00453-z","url":null,"abstract":"<div><h3>Background</h3><p>The androgen receptor (AR) is upregulated in multiple cancers, such as salivary gland cancer, glioblastoma, triple-negative breast cancer, and, most commonly, prostate cancer. Imaging expression of the AR using a radiolabeled AR antagonist would enable non-invasive clinical staging and assessment of tumor heterogeneity via positron emission tomography (PET), complementing the findings of a [<sup>68</sup>Ga]PSMA-11 scan. Previous efforts described the radiolabeling of enzalutamide with fluorine-18 but were limited by low molar activity. In this study, we showcase an efficient, reproducible automated synthesis of [<sup>18</sup>F]fluoroflutamide via zinc-mediated radiofluorination and assess its biodistribution in preclinical models of prostate cancer.</p><h3>Results</h3><p>From 1.87 Ci (69.19 GBq) of [<sup>18</sup>F]fluoride, [<sup>18</sup>F]fluoroflutamide was isolated with a non-decay-corrected radiochemical yield of 3.46 ± 1.30% (<i>n</i> = 4) and a radiochemical purity of > 99% in an average 79 min from end-of-beam using a bromoamide precursor. The average A<sub>m</sub> was 1.57 Ci/µmol (or 58.23 GBq/µmol) at the end of synthesis, and the radiochemical purity after 4 h was > 97%, indicating negligible radiolysis. A biodistribution and imaging study was performed using nude athymic mice with 22Rv1 human prostate cancer xenografts. From the results of this study, we observed a ‘mass effect’ in which carrier-added mice displayed an increased uptake of the tracer across most organs.</p><h3>Conclusions</h3><p>Herein, we report the optimized automated radiosynthesis of [<sup>18</sup>F]fluoroflutamide with high purity and sufficient yield for preclinical evaluation of AR-targeted imaging in mouse models of prostate cancer. The lack of uptake in androgen receptor-rich tissues and xenografts suggests impaired in vivo target engagement. While α-tertiary fluorination may attenuate CYP1A2-mediated oxidation to the higher-affinity 2-hydroxyflutamide metabolite, the observed signal is also consistent with reduced intrinsic AR affinity and/or altered pharmacokinetics of the fluorinated analog.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marianna Dakanali, Henry F. VanBrocklin, Steven S. Zigler, Peter J. H. Scott
{"title":"Assessment of PET drug adverse events in the U.S. since the implementation of 21 CFR part 212","authors":"Marianna Dakanali, Henry F. VanBrocklin, Steven S. Zigler, Peter J. H. Scott","doi":"10.1186/s41181-026-00482-8","DOIUrl":"10.1186/s41181-026-00482-8","url":null,"abstract":"<div><h3>Background</h3><p>Multiple new Positron Emission Tomography (PET) radiopharmaceuticals (RPhs) have recently been approved by the U.S. Food and Drug Administration (FDA). Despite the generally accepted safety profile of PET RPhs supported by millions of doses administered per year, the microdoses used in most injections, and the low incidence of adverse events (AEs), there appear to be elevated concerns from regulatory authorities regarding the safety of PET RPhs in recent years. There have been prior reports on the prevalence of AEs from RPhs, but most of them are outdated and do not reflect the current state-of-the-art and best practices. To address the gap, this retrospective study assesses risks associated with PET RPhs by reviewing AEs reported to the FDA Adverse Events Reporting System (FAERS) since the implementation of the PET good manufacturing practice (GMP) regulations in 21 CFR 212 in 2012. Data for AEs reported for approved PET RPhs were collected from the FAERS database. Data were collected during December 2025 for AEs reported between 2012 and 2024. FDA approved PET RPhs were searched using all known names for each drug. For each RPh, the following tables were downloaded from the database: (a) case count by received year; (b) cases by reaction; and (c) listing of cases. Tables downloaded for each radiopharmaceutical were combined, and duplicated entries removed. AE reports were then categorized based on the manufacturing regulatory oversight and, for the purposes of this report, we focused on AEs reported for 10 PET RPhs manufactured under 21 CFR 212.</p><h3>Results</h3><p>Almost 24 million adverse event reports for all drug products were transmitted to FDA between 2012 and 2024. Of these, 932 (or 0.0039%) were AEs submitted to FAERS for FDA-approved PET RPhs manufactured in the US. Of these AEs, 451 were reported for PET RPhs manufactured under 21 CFR 212. This represents approximately 7.0 AEs per 10<sup>5</sup> RPh injections performed in 2024 for all PET RPhs or 4.3/10<sup>5</sup> for PET RPhs manufactured under the PET GMP regulations. At least one adverse reaction to the RPh was reported in 237 of the 451 cases recorded, and two-thirds of these (157, 66.2%) were characterized as non-serious.</p><h3>Conclusions</h3><p>The FAERS data confirm that PET RPhs can be generally recognized as safe and effective. The extremely low numbers of AEs for PET RPhs manufactured according to 21 CFR 212 and the lack of correlation between manufacturing issues and safety AEs overall support a low risk profile for this class of drugs. Moreover, these data do not appear to justify significant changes to the existing regulations, or more stringent regulation of PET drug manufacture beyond those currently in place.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guilhem Claude, Matthias Balzer, Winfried Brenner, Frank Bruchertseifer, Alfred Morgenstern, David Thonon, Sarah Spreckelmeyer
{"title":"Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters in 225Ac-radiopharmaceutical","authors":"Guilhem Claude, Matthias Balzer, Winfried Brenner, Frank Bruchertseifer, Alfred Morgenstern, David Thonon, Sarah Spreckelmeyer","doi":"10.1186/s41181-026-00476-6","DOIUrl":"10.1186/s41181-026-00476-6","url":null,"abstract":"<div><h3>Background</h3><p>Analytical data for <sup>225</sup>Ac-labeled radiopharmaceuticals are currently obtained using thin-layer chromatography and high-performance liquid chromatography, the latter followed by offline fraction collection and delayed gamma-counting after secular equilibrium with gamma-emitting daughters has been reached. These procedures are slow and do not depict the distribution of daughter radionuclides. An inline HPLC detection setup combining liquid scintillation detection and LaBr<sub>3</sub>-based gamma-spectroscopy is presented to enable faster and more informative analysis of a <sup>225</sup>Ac radiopharmaceutical.</p><h3>Results</h3><p>Four chromatographic signals were identified corresponding to uncomplexed <sup>221</sup>Fr with at most a minor contribution of free <sup>213</sup>Bi, [<sup>213</sup>Bi]Bi-PSMA I&T, [<sup>225</sup>Ac]Ac-PSMA I&T, and [<sup>209</sup>Pb]Pb-PSMA I&T. The retention times corresponded to those of the non-radioactive analogs determined by UV detection. Assignments were confirmed by fraction collection followed by gamma-spectroscopy and beta liquid scintillation counting. The distribution of these species changed upon heating the reaction mixture or after addition of another ligand.</p><h3>Conclusions</h3><p>The combined detection setup enables rapid observation of isotope distribution and daughter behavior during chromatographic analysis and avoids fraction handling by operating as a closed system, thereby reducing contamination risk and radiation exposure. This approach may contribute to improved quality control procedures for <sup>225</sup>Ac radiopharmaceuticals and other alpha-emitting radionuclides. At the present stage, however, it should be regarded as a qualitative to semi-quantitative proof-of-principle.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}